New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

Of the 16 patients (67%) in whom an anastomosis was not successfully created, the ischemic form of central retinal vein occlusion developed in five (31%), and eight (50%) were left with various ...

Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with central, branch, and hemiretinal vein occlusions. The data from this trial will support a ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

South Korea-based Celltrion today announced that the European Commission (EC) has granted marketing authorization for three ...

8mg injection in treating individuals with macular oedema following retinal vein occlusion (RVO). The trial met the primary endpoint of mean change in best corrected visual acuity (BCVA ...

age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation ...

due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and due to choroidal neovascularization (CNV). Lucentis Important Safety ...

Chattisgarh High Court held that considering FIR and other material the accused involvement in illegal coal levy collection ...

The mechanic and father of four, from the outback town of Barcaldine in central west Queensland ... “(Branch retinal vein occlusion) is something that could possibly get out of control, and ...